TLON Will Continue To Push Higher With Typical Backing And Filling Pending The Goldman Sachs Recomendation
The stage is set, folks. Once Goldman Sachs determines the best course of action for TLON in view of the recent FDA approval for Marqibo, investors here will see this stock spike to the upside very quickly to well above the $1.00/share point. Making sure one is appropriately positioned at this point to take advantage of this coming event would be in your best interest. I'm looking for this event to happen in the days/weeks ahead. Stay tuned everyone.